ResMed Scores Legal Wins in Patent Spat with NYU

ResMed announced it secured a “significant victory” following a U.S. Patent Trial and Appeals Board (PTAB) ruling that invalidated the claims New York University (NYU) asserted against the company, based on seven NYU patents.
 
In June 2021, NYU alleged patent infringement against ResMed in the U.S. District Court, District of Delaware. NYU’s complaint claimed the AutoSet and AutoRamp features of ResMed’s AirSense 10 AutoSet flow generators infringed one or more claims of seven NYU patents.
 
ResMed then filed petitions with the PTAB claiming all the allegations against it were invalid. In rulings issues from December 4 to December 7, 2023, the PTAB judges agreed with ResMed’s arguments and found all challenged claims across the seven patents were invalid.
 
“At ResMed, we’re committed to providing patients with our leading therapy solutions. Our sustained investment in research and development for over 30 years has culminated in more than 9,500 issued or pending patents and designs,” said Mick Farrell, ResMed’s CEO. “We applaud the PTAB’s ruling and will defend our innovations, ensuring patients continue to receive our therapy solutions, empowering them to live healthier, higher-quality lives.”
 
“We will continue to vigorously defend our innovations,” added Michael Rider, ResMed’s global general counsel and secretary. “The fact that our intellectual property contributed to this victory is a testament to our investment in research and development, the hard work of our inventors, and the patent protection we pursue to protect our innovation.”